title: Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study.
abstract: OBJECTIVE
  Changes in cognitive function have been identified in and reported by many cancer survivors. These changes have the potential to impact patient quality of life and functional ability. This prospective longitudinal study was designed to quantify the incidence of change in cognitive function in newly diagnosed ovarian cancer patients throughout and following primary chemotherapy.
  
  
  METHODS
  Eligible patients had newly diagnosed, untreated ovarian cancer and had planned to receive chemotherapy. Web-based and patient reported cognitive assessments and quality of life questionnaires were conducted prior to chemotherapy, prior to cycle four, after cycle six, and six months after completion of primary therapy.
  
  
  RESULTS
  Two-hundred-thirty-one evaluable patients entered this study between May 2010 and October 2011. At the cycle 4 time point, 25.2% (55/218) of patients exhibited cognitive impairment in at least one domain. At the post-cycle 6 and 6-month follow up time points, 21.1% (44/208) and 17.8% (30/169) of patients, respectively, demonstrated impairment in at least one domain of cognitive function. There were statistically significant, but clinically small, improvements in processing speed (p<0.001) and attention (p<0.001) but not in motor response time (p=0.066), from baseline through the six-month follow up time period.
  
  
  CONCLUSIONS
  This was a large, prospective study designed to measure cognitive function in ovarian cancer. A subset of patients had evidence of cognitive decline from baseline during chemotherapy treatment in this study as measured by the web-based assessment; however, changes were generally limited to no more than one domain.
authors.affiliation: Indiana University School of Medicine, Indianapolis, IN 46202, United States. Electronic address: lmhess@iupui.edu.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Hess
authors.affiliation: NRG Oncology/Gynecologic Oncology Group Statistics and Data Center, Buffalo, NY, United States. Electronic address: hhuang@gogstats.org.
authors.forename: Helen Q
authors.initials: HQ
authors.lastname: Huang
authors.affiliation: University of Pennsylvania, Philadelphia, PA, United States. Electronic address: al_hanlon@comcast.net.
authors.forename: Alexandra L
authors.initials: AL
authors.lastname: Hanlon
authors.affiliation: Tulane University, New Orleans, LA, United States. Electronic address: wrobinso@tulane.edu.
authors.forename: William R
authors.initials: WR
authors.lastname: Robinson
authors.affiliation: Kansas University Medical Center, Kansas City, KS, United States. Electronic address: rjohnson7@kumc.edu.
authors.forename: Rhonda
authors.initials: R
authors.lastname: Johnson
authors.affiliation: University of Arizona Cancer Center, Tucson, AZ, United States. Electronic address: schambers@uacc.arizona.edu.
authors.forename: Setsuko K
authors.initials: SK
authors.lastname: Chambers
authors.affiliation: The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. Electronic address: Robert-mannel@ouhsc.edu.
authors.forename: Robert S
authors.initials: RS
authors.lastname: Mannel
authors.affiliation: Greenville CCOP, Greenville, NC, United States. Electronic address: lpuls@ghs.org.
authors.forename: Larry
authors.initials: L
authors.lastname: Puls
authors.affiliation: University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, CO, United States. Electronic address: susan.davidson@ucdenver.edu.
authors.forename: Susan A
authors.initials: SA
authors.lastname: Davidson
authors.affiliation: Northern Indiana CCOP, Mishawaka, IN, United States. Electronic address: mmethod@mhopc.com.
authors.forename: Michael
authors.initials: M
authors.lastname: Method
authors.affiliation: Roswell Park Cancer Institute, Buffalo, NY, United States. Electronic address: Shashi.lele@roswellpark.org.
authors.forename: Shashikant
authors.initials: S
authors.lastname: Lele
authors.affiliation: Duke University Medical Center, Durham, NC, United States. Electronic address: havri001@mc.duke.edu.
authors.forename: Laura
authors.initials: L
authors.lastname: Havrilesky
authors.affiliation: The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. Electronic address: tina-nelson@ouhsc.edu.
authors.forename: Tina
authors.initials: T
authors.lastname: Nelson
authors.affiliation: University of Arizona Cancer Center, Tucson, AZ, United States. Electronic address: dalberts@uacc.arizona.edu.
authors.forename: David S
authors.initials: DS
authors.lastname: Alberts
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001288:Attention / Q000187:drug effects; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000139:chemically induced*; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000523:psychology; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D011446:Prospective Studies; D011788:Quality of Life; D011930:Reaction Time / Q000187:drug effects; D011795:Surveys and Questionnaires; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents
keywords: Chemotherapy; Cognitive function; Ovarian cancer; Prospective trial; Quality of life